The study of the regulatory and legal framework for the activities of the authorized person on implementation of pharmaceutical provision in healthcare institutions and identification of the areas for the improvement

Abstract

Aim. To study the activity of the authorized person on implementation of pharmaceutical provision (PP) in healthcare institutions (HCI) in Kharkiv, its regulatory and legal regulation, and determine the areas for improving the implementation of PP in HCI.Materials and methods. During the study the methods of analysis, systematization and generalization, data of official websites of branch state organizations, scientific literature were used.Results. In modern conditions for organizing and performing PP in HCI the administration appoints authorized persons who are involved in control of the turnover, the drug quality, accounting of drugs and medical products (MP), etc. During the study the analysis of the activities of the authorized person with PP in HCI, his duties and the possibility of their implementation has been performed. It has been found that the authorized person directly participates in the organization, control and planning of PP in HCI. The results of the study have shown that the presence of the authorized person has a direct impact on reducing the number of breaking the storage conditions for medicines in the process of their storage in HCI, reducing the number of low-quality medicines. It promotes compliance with the state control over implementation of the requirements of legislation by HCI in order to provide the drug quality. It has been also found that the load on authorized persons with PP in HCI increases by setting more stringent requirements for control over the turnover, drug quality, and accounting of medicines and MP.Conclusions. The presence of the authorized person on implementation of PP in HCI makes it possible to ensure the fulfillment of a number of mandatory conditions for implementation of a proper PP, in particular providing the proper storage of medicines; prevention of the use of low-quality medicines in HCI, a strict control over the shelf-life of medicines and prevention of the use of medicines with the expired shelf life; improvement of control over observance of storage conditions of drugs in HCI; reduction of the number of breaking the storage conditions for medicines in the process of their turnover in HCI; providing patients with quality and safe medicines; timely informing the HCI administration about the progress of implementation of PP, etc.